INBX logo

Inhibrx, Inc. Common Stock

INBX

INBX: Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.

more

Show INBX Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of INBX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by INBX's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Pdl1-binding proteins Jan. 31, 2023
  • Patent Title: Cd33-binding polypeptides and uses thereof Jan. 24, 2023
  • Patent Title: Cd123-binding polypeptides and uses thereof Sep. 06, 2022
  • Patent Title: Pd-1 single domain antibodies and therapeutic compositions thereof Dec. 28, 2021
  • Patent Title: Multivalent and multispecific dr5-binding fusion proteins and methods of treating neoplasms Sep. 14, 2021
  • Patent Title: Multivalent and multispecific ox40-binding fusion proteins Sep. 14, 2021
  • Patent Title: Serpin fusion polypeptides and methods of use thereof Jun. 29, 2021
  • Patent Title: Multivalent and multispecific glucocorticoid-induced tnfr-related protein (gitr)-binding single-domain antibody fusion proteins and encoding nucleic acids Nov. 24, 2020
  • Patent Title: Type iii secretion system targeting molecules Aug. 18, 2020
  • Patent Title: Serpin fusion polypeptides and methods of use thereof Aug. 04, 2020
  • Patent Title: Serpin fusion polypeptides and methods of use thereof Jul. 28, 2020
  • Patent Title: Non-immunogenic single domain antibodies Jan. 07, 2020
  • Patent Title: Multivalent and multispecific 41bb-binding fusion proteins Dec. 10, 2019
  • Patent Title: Serpin fusion polypeptides and methods of use thereof Sep. 03, 2019
  • Patent Title: Type iii secretion system targeting molecules Jul. 09, 2019
  • Patent Title: Multivalent and multispecific dr5-binding fusion proteins Jun. 04, 2019
  • Patent Title: Multispecific gitr-binding fusion proteins and methods of use thereof Oct. 09, 2018
  • Patent Title: Serpin fusion polypeptides and methods of purification thereof Mar. 20, 2018
  • Patent Title: Wap domain fusion polypeptides and methods of use thereof Mar. 13, 2018
  • Patent Title: Cd47 antibodies and methods of use thereof May. 30, 2017
  • Patent Title: Cd47 antibodies and methods of use thereof Jun. 02, 2015
  • Patent Title: Wap domain fusion polypeptides and methods of use thereof Mar. 24, 2015
  • Patent Title: Serpin fusion polypeptides and methods of use thereof Mar. 17, 2015
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of INBX in WallStreetBets Daily Discussion

INBX News

Recent insights relating to INBX

CNBC Recommendations

Recent picks made for INBX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in INBX

Corporate Flights

Flights by private jets registered to INBX